725 related articles for article (PubMed ID: 25328959)
1. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
2. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Jul; ():. PubMed ID: 25198789
[TBL] [Abstract][Full Text] [Related]
3. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
4. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
5. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Abrahão AC; Giudice FS; Sperandio FF; Pinto Junior Ddos S
J Oral Pathol Med; 2013 Nov; 42(10):793-8. PubMed ID: 23679684
[TBL] [Abstract][Full Text] [Related]
6. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K; Ren P
Oncol Rep; 2015 Mar; 33(3):1079-88. PubMed ID: 25524805
[TBL] [Abstract][Full Text] [Related]
9. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Zhao Y; Hao Y; Ji H; Fang Y; Guo Y; Sha W; Zhou Y; Pang X; Southerland WM; Califano JA; Gu X
Cancer Prev Res (Phila); 2010 Jun; 3(6):787-96. PubMed ID: 20501859
[TBL] [Abstract][Full Text] [Related]
10. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Sui W; Zhang Y; Wang Z; Wang Z; Jia Q; Wu L; Zhang W
Oncol Rep; 2014 May; 31(5):2252-60. PubMed ID: 24647425
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells.
Abdallah FM; Helmy MW; Katary MA; Ghoneim AI
Naunyn Schmiedebergs Arch Pharmacol; 2018 Dec; 391(12):1399-1410. PubMed ID: 30155693
[TBL] [Abstract][Full Text] [Related]
14. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
15. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
[TBL] [Abstract][Full Text] [Related]
17. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
18. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K
Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
[TBL] [Abstract][Full Text] [Related]
19. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
[TBL] [Abstract][Full Text] [Related]
20. Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Velmurugan BK; Hua CH; Tsai MH; Lee CP; Chung CM; Ko YC
Biotech Histochem; 2020 Jul; 95(5):341-348. PubMed ID: 31937145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]